How North Sea tanker crash could impact wildlife-rich coastline
Academics have raised fears over the ecological impact the dramatic crash involving an oil tanker and cargo vessel could have on the Norfolk coastline.
The two ships – including one carrying jet fuel - went up in flames in the North Sea off the coast of East Yorkshire on Monday.
Although the air quality at ground level has been recorded as at normal levels, experts said the event could damage the environment of the protected Norfolk coastline.
Environmental biologist Prof Ben Garrod said "we should be doing all we can to ensure this never happens again".
Thirty six people were rescued from the collision and one crew member remained unaccounted for.
Prof Garrod, from the University of East Anglia's School of Biological Sciences, said the coast's shallow bay, The Wash, could be particularly impacted.
"The Wash is recognised for its local, national and international ecological importance for flora and fauna alike," he said.
"Some migrate there, others breed there, and for many species of plants, fungi, and animals, it's home.
"The possible addition of tonnes of highly soluble toxic material which shuts down the respiration system into such a fragile and important habitat will likely have far-reaching impacts on our local wildlife, especially fish, birds and mammals.
"We should be doing all we can to monitor the impact that the release of tonnes of ecologically damaging chemicals has on our fragile marine environment."
The collision occurred at about 10:00 GMT, sparking fires and a mass evacuation, with one crew member saying the incident "came from out of the blue".
The Stena Immaculate ship, the US-flagged oil and chemical tanker, was carrying jet fuel on behalf of the US military.
The Solong meanwhile, a Portuguese-flagged container vessel, denied that it was transporting 15 containers of sodium cyanide.
"There are four empty containers that have previously contained the hazardous chemical and these containers will continue to be monitored," said Ernst Russ, the ship's owner.
Dr Paul Johnston, senior scientist at Greenpeace Research Laboratories at the University of Exeter, said he was "very concerned".
"The wind is blowing from the north and will drive any material that is released towards the north Norfolk coast," he told the BBC Radio 4 Today programme.
"There are bird colonies, there will be seals hauled out, dolphins and porpoises passing through the area and animals, together with fish and marine vertebrate.
"[They will] all be very vulnerable to toxic events, from both oils and chemicals."
Videos from the scene showed large clouds of smoke billowing out from the tanker, and the firm which managed the Stena Immaculate reported "multiple explosions".
"The jet fuel will continue burning [but] the heavy fuel oil is more of a problem if it comes ashore - it will fell beaches and be very difficult to clean up," added Dr Johnston.
"Any containers that go over the side are likely to be a navigational hazard in so far as any ship that strikes them could become disabled or even sink."
When asked if he thought this could result in the largest environmental disaster for a generation, he said it was a "very difficult thing to predict".
"And that's why so much effort is being put into salvage efforts in order to minimise the amount of material entering the sea.
"An ounce of prevention is worth many tonnes of cure but what we can learn from previous events in terms of clean-up is that it is very, very difficult."
Prof Alastair Grant, from the University of East Anglia's school of environmental sciences, said "a detailed evaluation" of the environmental risks posed by the jet fuel would need to be conducted.
"It contains up to 25% aromatic hydrocarbons, which are relatively toxic and slow to break down in the environment," he said.
"This makes it approximately 50 times more toxic to aquatic life than diesel oil, which in turn is more toxic than crude oil."
These concerns were also echoed by the Norfolk Wildlife Trust (NWT), which said "any pollution spillage could be devastating" for habitats in the area.
A spokesperson said: "Depending on wind direction and contaminants, The Wash and North Norfolk coast, including NWT Holme Dunes nature reserve could potentially be at risk.
"These areas are home to internationally important populations of seabirds and fragile habitats.
"We'll continue to keep a close eye on the situation and work with marine authorities if needed."
While the incident happened in UK waters, the responsibility for the investigation will fall to the United States and Portugal.
The Marine Accident Investigation Branch, however, is already gathering evidence and undertaking a preliminary assessment of the accident.
The Maritime and Coastguard Agency (MCA) is also "rapidly assessing" the potential environment impact of the collision.
When it is considered safe to do so, the BBC understands the MCA will deploy equipment to contain and disperse the oil spills.
The government agency is also working with the owners of the ships and the Department for Transport to understand potential risks to public health.
According to the UK Health Security Agency (UKHSA), any public health risk on shore is deemed to be very low.
Labour MP Heidi Alexander, the transport secretary, said she was grateful to HM Coastguard, the RNLI and emergency services for their response.
"They were on the scene swiftly, have helped rescue those in immediate danger and I know they will continue to work tirelessly over the coming days.
"My thoughts are with all those involved, especially the family of the missing crew member.
"I am working closely with the MCA as they conduct an assessment of any counter pollution response which may be required over the coming days."
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
North Sea tanker collision - what we know so far
Search for ship collision crew member called off
Maritime and Coastguard Agency
Marine Accident Investigation Branch
Department for Transport
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
an hour ago
- Yahoo
Japan's ispace tries lunar touchdown again with Resilience lander
By Kantaro Komiya TOKYO (Reuters) -Japanese company ispace is set to try the lunar touchdown of its uncrewed spacecraft again on Friday two years after its failed inaugural mission, in a bid to become the first company outside the United States to achieve a moon landing. Tokyo-based ispace hopes to join U.S. firms Intuitive Machines and Firefly Aerospace, which have accomplished commercial landings amid an intensifying global race for the moon that includes state-run missions from China and India. Resilience, ispace's second lunar lander, is expected to touch down on Mare Frigoris, a basaltic plain about 900 km (560 miles) from the moon's north pole, at 4:17 a.m. Friday local time (1917 GMT Thursday) following an hour-long descent from lunar orbit, according to the company. In 2023, ispace's first lander crashed into the moon's surface due to inaccurate recognition of its altitude. Software remedies have been implemented, while the hardware design is mostly unchanged in Resilience, the company has said. Resilience carries a four-wheeled rover built by ispace's Luxembourg subsidiary and payloads worth a total of $16 million, including scientific instruments from Japanese firms and a Taiwanese university. If the landing is successful, the 2.3-metre-high lander and the microwave-sized rover will begin 14-day exploration activities until the arrival of a freezing-cold lunar night, including capturing images of regolith, the moon's fine-grained surface material, on a contract with U.S. space agency NASA. Later on Friday, ispace will host a press conference about the outcome of the mission, according to the company. Shares in ispace more than doubled earlier this year on growing investor hopes for the second mission, before calming in recent days. Resilience in January shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which took a faster trajectory to the moon and touched down successfully in March. Intuitive Machines, which last year marked the world's first touchdown of a commercial lunar lander, made its second attempt in March but the lander Athena ended on its side on the lunar surface just as in the first mission. Japan last year became the world's fifth country to achieve a soft lunar landing after the former Soviet Union, the U.S., China and India, when the national Japan Aerospace Exploration Agency (JAXA) achieved the touchdown of its SLIM lander, yet also in a toppled position. Despite President Donald Trump's proposed changes to the U.S. space policy, Japan remains committed to NASA's Artemis moon program, pledging the involvement of Japanese astronauts and technologies for future lunar missions. Including one in 2027 as part of the Artemis program, ispace plans seven more missions in the U.S. and Japan through 2029 to capture increasing demands for lunar transportation.
Yahoo
2 hours ago
- Yahoo
Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR
DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period. The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing applications of synthesized oligonucleotides in therapeutics & diagnostics. This growth is supported by technological advancements and rising investments in life sciences research and synthetic biology. Additionally, the growing emphasis on precision and personalized medicine contributes to this expansion, creating new opportunities as key players increase their research and development investments in emerging economies. Download PDF Brochure: Browse in-depth TOC on "Oligonucleotide Synthesis Market" 568 - Tables 77 - Figures 455 - Pages By product, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. These have seen rapid clinical & commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst & investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines. The central importance of developing the oligonucleotide therapy scene is pronounced by high yields, reduced manufacturing complexity, and known delivery platforms, thus contributing to market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to the rising demand for oligonucleotide-based drugs for rare & neurological diseases, primarily owing to the increasing target patient population. The significant share of this segment reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious & chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals. By geography, in 2024, North America accounted for the largest share of the oligonucleotide synthesis market owing to its presence of strong regional players who have advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals granted with supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers for upscaling production are also expected to be growth drivers for this regional segment. Request Sample Pages : Some of the leading players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others. Danaher Corporation (US): One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion. Thermo Fisher Scientific (US) Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America. Biogen (US) Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome. For more information, Inquire Now! Related Reports: Next Generation Sequencing Market Synthetic Biology Market Genomics Market Molecular Diagnostics Market Biomarkers Market Get access to the latest updates on Oligonucleotide Synthesis Companies and Oligonucleotide Synthesis Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Visit Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR
DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period. The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing applications of synthesized oligonucleotides in therapeutics & diagnostics. This growth is supported by technological advancements and rising investments in life sciences research and synthetic biology. Additionally, the growing emphasis on precision and personalized medicine contributes to this expansion, creating new opportunities as key players increase their research and development investments in emerging economies. Download PDF Brochure: Browse in-depth TOC on "Oligonucleotide Synthesis Market" 568 - Tables 77 - Figures 455 - Pages By product, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. These have seen rapid clinical & commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst & investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines. The central importance of developing the oligonucleotide therapy scene is pronounced by high yields, reduced manufacturing complexity, and known delivery platforms, thus contributing to market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to the rising demand for oligonucleotide-based drugs for rare & neurological diseases, primarily owing to the increasing target patient population. The significant share of this segment reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious & chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals. By geography, in 2024, North America accounted for the largest share of the oligonucleotide synthesis market owing to its presence of strong regional players who have advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals granted with supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers for upscaling production are also expected to be growth drivers for this regional segment. Request Sample Pages : Some of the leading players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others. Danaher Corporation (US): One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion. Thermo Fisher Scientific (US) Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America. Biogen (US) Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome. For more information, Inquire Now! Related Reports: Next Generation Sequencing Market Synthetic Biology Market Genomics Market Molecular Diagnostics Market Biomarkers Market Get access to the latest updates on Oligonucleotide Synthesis Companies and Oligonucleotide Synthesis Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Visit Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio